Citadel Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-278,700
| Closed | -$635K | – | 15549 |
|
|
2024
Q2 | $635K | Buy |
278,700
+189,600
| +213% | +$724K | ﹤0.01% | 7553 |
|
|
2024
Q1 | $385K | Buy |
89,100
+39,000
| +78% | +$136K | ﹤0.01% | 8935 |
|
|
2023
Q4 | $153K | Sell |
50,100
-15,900
| -24% | -$29.9K | ﹤0.01% | 10351 |
|
|
2023
Q3 | $95K | Buy |
66,000
+39,700
| +151% | +$76.8K | ﹤0.01% | 10962 |
|
|
2023
Q2 | $65.5K | Sell |
26,300
-32,000
| -55% | -$87.4K | ﹤0.01% | 11484 |
|
|
2023
Q1 | $156K | Buy |
58,300
+10,500
| +22% | +$50.5K | ﹤0.01% | 10571 |
|
|
2022
Q4 | $260K | Buy |
47,800
+22,600
| +90% | +$189K | ﹤0.01% | 9621 |
|
|
2022
Q3 | $315K | Buy |
+25,200
| New | +$288K | ﹤0.01% | 9470 |
|
|
2022
Q2 | – | Sell |
-26,000
| Closed | -$198K | – | 14395 |
|
|
2022
Q1 | $198K | Sell |
26,000
-15,200
| -37% | -$144K | ﹤0.01% | 11559 |
|
|
2021
Q4 | $421K | Buy |
41,200
+13,000
| +46% | +$166K | ﹤0.01% | 10091 |
|
|
2021
Q3 | $378K | Sell |
28,200
-34,100
| -55% | -$556K | ﹤0.01% | 10552 |
|
|
2021
Q2 | $1.37M | Buy |
62,300
+2,800
| +5% | +$62.2K | ﹤0.01% | 7541 |
|
|
2021
Q1 | $1.43M | Buy |
59,500
+6,500
| +12% | +$151K | ﹤0.01% | 7221 |
|
|
2020
Q4 | $953K | Buy |
+53,000
| New | +$792K | ﹤0.01% | 6900 |
|
Citadel Advisors's GTHX Position: Q3 2024 in Review
Citadel Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 239 shares — an estimated $545 sold.
Citadel Advisors first reported a position in GTHX in Q1 2018 and held it in 25 quarters. The position peaked at $4.62M in Q1 2019. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Citadel Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Citadel Advisors sold 239 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $545.
- Citadel Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 25 quarters.
- Citadel Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $4.62M in Q1 2019.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.